MoneyWorks4Me

Zydus Lifesciences soars on reporting 9% rise in Q4 consolidated net profit

20 May 2026 Evaluate

Zydus Lifesciences is currently trading at Rs. 1077.35, up by 58.40 points or 5.73% from its previous closing of Rs. 1018.95 on the BSE.

The scrip opened at Rs. 1056.15 and has touched a high and low of Rs. 1,083.00 and Rs. 1044.05 respectively. So far 125731 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,083.00 on 20-May-2025 and a 52 week low of Rs. 835.85 on 02-Apr-2026.

Last one week high and low of the scrip stood at Rs 1,083.00 and Rs. 890.00 respectively. The current market cap of the company is Rs. 102530.21 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.86% respectively.

Zydus Lifesciences has reported 38.80% fall in its net profit at Rs 1,722.00 crore for the fourth quarter ended March 31, 2026 as compared to Rs 2,813.70 crore for the same quarter in the previous year. The total income of the company has decreased by 29.46% at Rs 4,236.00 crore for Q4FY26 as compared to Rs 6,005.00 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 8.68% rise in its net profit at Rs 1,272.50 crore for the fourth quarter ended March 31, 2026 as compared to Rs 1,170.90 crore for the same quarter in the previous year. The total income of the company increased by 16.84% at Rs 7,721.20 crore for Q4FY26 as compared to Rs 6,608.50 crore for the corresponding quarter previous year.

For the year ended March 31, 2026, the company has reported 38.36% fall in its net profit at Rs 3,559.80 crore as compared to Rs 5,774.90 crore for the previous year. The total income of the company has decreased by 16.83% at Rs 13,151.50 crore for year under review as compared to Rs 15,812.50 crore for year ended March 31, 2025.

For the year ended March 31, 2026, on the consolidated basis, the company has reported 11.37% rise in its net profit at Rs 5,040.00 crore as compared to Rs 4,525.50 crore for the previous year. The total income of the company increased by 17.64% at Rs 27,657.90 crore for year under review as compared to Rs 23,511.00 crore for year ended March 31, 2025.

Peers
Company Name CMP
Sun Pharma. Inds. 1840.00
Dr. Reddys Labs. 1222.50
Cipla 1388.90
Lupin 2061.85
Zydus Lifesciences 1212.00
View more..